Compare SFBC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBC | STRO |
|---|---|---|
| Founded | 1953 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.1M | 85.0M |
| IPO Year | 2012 | N/A |
| Metric | SFBC | STRO |
|---|---|---|
| Price | $42.77 | $20.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 3.9K | ★ 116.6K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.40 | $0.52 |
| 52 Week High | $51.89 | $20.59 |
| Indicator | SFBC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 73.10 |
| Support Level | N/A | $0.76 |
| Resistance Level | $44.50 | N/A |
| Average True Range (ATR) | 0.42 | 1.70 |
| MACD | -0.14 | 0.27 |
| Stochastic Oscillator | 17.22 | 94.68 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.